University of Southern California

Techniclone, Inc.

Cancer Biologics, Inc.

Northwestern University

Alan L Epstein

Peisheng Hu

Leslie A Khawli

Clive R Taylor

Michael Glovsky

Peishing Hu

Jiali Li

Melissa G Lechner

Jacek K Pinski

John Andrew MacKay

Suhaas Aluri

John Ohlfest

Long Zheng

Provided herein are antibodies and chimeric antigen receptor (CAR) cells comprising the antigen binding domains of these antibodies. Also provided are compositions comprising the same, vector or plasmid encoding the antibodies and CARs, and methods for producing the same, or using the same for detecting or treating cancer and kits for carrying out said methods.

Lym-1 and Lym-2 antibody compositions and improved car constructs

Provided herein are novel anti-LHR chimeric antigen receptor (CAR), cells or compositions comprising the same, vector or plasmid encoding anti-LHR CAR, and methods for producing the same, or using the same for detecting or treating ovarian cancer or prostate cancer. Also provided herein are anti-LHR antibody, compositions comprising the same, nucleic acid sequence encoding the same, and a kit for detecting LHR.

Car t-cell therapy directed to LHR for the treatment of solid tumors

Disclosed herein are recombinant polypeptides comprising an elastin-like peptide (ELP) and a scFv, or a biological equivalent of the scFv. Also disclosed are compositions containing scFv-ELP polypeptides and methods of use.

CD20 scFv-ELPs methods and therapeutics

CAR cells targeting and antibodies human HLA-DR are described as a new method of cancer treatment. It is proposed that HLA-DR CAR cells are safe and effective in patients and can be used to treat human tumors expressing the HLA-DR.

Lym-1 and Lym-2 targeted CAR cell immunotherapy

Provided is an isolated recombinant polypeptide comprising an immunoglobulin domain and a canine OX40L extracellular domain polypeptide fragment or a biological equivalent thereof and compositions comprising: an isolated recombinant polypeptide comprising an immunoglobulin domain and a canine OX40L extracellular domain polypeptide fragment; and a pharmaceutically acceptable carrier. Also provided are methods for treating or ameliorating the symptoms of cancer in a canine comprising administering an effective amount of the isolated recombinant polypeptide of the disclosure and/or a composition of the disclosure to a canine in need thereof.

OX40L fusion protein for the immunotherapy of tumors of veterinary animals

Provided herein are methods for determining the presence of cancer (malignant versus benign), monitoring the progression of cancer, monitoring cancer relapse, monitoring the response to cancer therapy, or cancer staging in a subject, by evaluating CD33/HLA-DR, CD14/HLA-DR, CD66b/HLA-DRor, CD11b/HLA-DRMDSC for activation of a transcription factor. Transcription factors include, but are not limited to, STAT3, pSTAT3, HIF1&#x3b1;, or C/EBP&#x3b2;. The MDSC phenotype can be CD33HLA-DRHIF1&#x3b1;/STAT3, CD14HLA-DRHIF1&#x3b1;/STAT3/pSTAT3/C/EBPb, CD66bHLA-DRHIF1&#x3b1;/STAT3/pSTAT3/C/EBPb, CD33HLA-DRHIF1&#x3b1;/STAT3/pSTAT3/C/EBPb, CD11bHLA-DRHIF1&#x3b1;/STAT3/pSTAT3/C/EBPb, or CD11bHLA-DRC/EBP&#x3b2;. Also provided herein are methods for inducing human MDSC from healthy donor peripheral blood mononuclear cells (PBMC) by co-culturing PBMC with human solid tumor cell lines and subsequently measuring their suppressive ability.

Human myeloid derived suppressor cell cancer markers

Provided is a cancer therapeutic agent comprising a cancer targeting molecule linked to a CpG oligodeoxynucleotide. Also provided are methods of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual or inhibiting the development of metastatic cancer, comprising administering an effective amount of the cancer therapeutic agent. The methods may also include reducing immunoregulatory T cell activity in the individual.

Cancer targeted innate immunity

Provided is a cancer therapeutic agent comprising a cancer targeting molecule linked to a liver-expressed chemokine (LEC). In one embodiment, the cancer targeting molecule is an antibody that targets cancer cells or tumors in vivo. The cancer targeting molecule is associated non-covalently or covalently with LEC. The cancer therapeutic agents of the invention are useful for the treatment of cancer in an individual by reducing the size of a tumor or inhibiting the growth of cancer cells in an individual and/or by inhibiting the development of metastasis. The effectiveness of the therapy using the LEC cancer therapeutic agents can be increased by reducing the activity of immunoregulatory T cells and/or by adoptively transferring immune T cells.

Compositions and methods for cancer immunotherapy

Provided are methods of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual or inhibiting the development of metastatic cancer by administering an effective amount of a soluble form of a co-stimulatory molecule from an antigen presenting cell and by reducing the activity of immunoregulatory T cells in the individual. Methods of reduction in the activity of immunoregulatory T cells involve removing them ex vivo or depleting or inactivating them in vivo. Also provided are cancer therapeutic compositions comprising a soluble form of a co-stimulatory molecule from an antigen presenting cell and an antibody specific for an intracellular antigen.

Combination cancer immunotherapy with co-stimulatory molecules

Interleukin-2 (IL-2) mutants having reduced toxicity, which include full-length IL-2, truncated forms of IL-2 and forms of IL-2 that are linked to another molecule are disclosed herein. Particular substitutions within IL-2, particularly within the permeability enhancing peptide region of IL-2 achieve substantial reduction of vasopermeability activity as compared to a wildtype form of the mutant IL-2 while retaining many of the immune activating properties of IL-2. Invention IL-2 mutants can be used to stimulate the immune system of an animal and may be used in the treatment of various disorders and conditions.

Methods of using interleukin-2 mutants with reduced toxicity

Interleukin-2 (IL-2) mutants having reduced toxicity, which include full-length IL-2, truncated forms of IL-2 and forms of IL-2 that are linked to another molecule are disclosed herein. Particular substitutions within IL-2, particularly within the permeability enhancing peptide region of IL-2 achieve substantial reduction of vasopermeability activity as compared to a wildytpe form of the mutant IL-2 while retaining many of the immune activating properties of IL-2. Invention IL-2 mutants can be used to stimulate the immune system of an animal and may be used in the treatment of various disorders and conditions.

Growing community of inventors

La Canada, CA, United States of America

Alan L Epstein